Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Medicus Pharma Ltd
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
June 11, 2026
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
June 8, 2026
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
June 3, 2026
Medicus Pharma Announces $22 Million Non-Dilutive Financing
May 28, 2026
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
March 5, 2026
Medicus Pharma on Bloomberg World
February 17, 2026
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
February 2, 2026
←
Previous Page
1
2
3